Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7524611 | 1.00 | RECQL (0.54) | RECQLMEN1KMT2AMAPTTHRB | |
| SCHEMBL6307440 | 1.00 | RECQL (0.54) | RECQLMEN1KMT2AMAPTTHRB | |
| SCHEMBL16449689 | 0.86 | RECQL (0.54) | RECQLMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL1915834 | 0.86 | RECQL (0.69) | RECQLMEN1KMT2AMAPTTHRB | |
| SCHEMBL1915838 | 0.86 | RECQL (0.69) | RECQLMEN1KMT2AMAPTTHRB | |
| SCHEMBL1915837 | 0.86 | RECQL (0.69) | RECQLMEN1KMT2AMAPTTHRB | |
| SCHEMBL5284839 | 0.86 | RECQL (0.54) | RECQLMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL6299382 | 0.84 | RECQL (0.53) | RECQLMEN1KMT2AMAPTTHRB | |
| SCHEMBL7377051 | 0.84 | RECQL (0.53) | RECQLMEN1KMT2AMAPTTHRB | |
| SCHEMBL6299379 | 0.84 | RECQL (0.53) | RECQLMEN1KMT2AMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906085-B2 | Tetrahydropyran derivatives as neurokinin receptor antagonists | MERCK SHARP & DOHME LTD. | 2005-06-14 | — | — | US | disclosed |
| US-20040063974-A1 | Tetrahydropyran derivatives as neurokinin receptor antagonists | MERCK SHARP & DOHME, LTD. (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1377565-A1 | TETRAHYDROPYRAN DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002057250-A1 | TETRAHYDROPYRAN DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063974-A1 | Tetrahydropyran derivatives as neurokinin receptor antagonists | NPSR1, OPRK1, CCKAR | RECQL 1753/4885MEN1 1138/4885KMT2A 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.